A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
Inclusion Criteria:
Exclusion Criteria:
Houston, Texas 77030, United States
Newport News, Virginia 23601, United States
Buenos Aries, 1704, Argentina
CABA, 1180, Argentina
Códoba, 5004, Argentina
Rio de Janeiro - RJ, 20220-410, Brazil
Pokfulam, Islands, Hong Kong
Hyderabaad, 500004, India
Naples, 80131, Italy
Shinjuku-Ku, Japan
Sunto-Gun, Japan
Sittard-Geleen, 6162 BG, Netherlands
Poznan, 61-878, Poland
Coimbra, 3000-075, Portugal
Ufa, 450054, Russia
Cherkasy, 18009, Ukraine